The global DNA & gene chip market size is expected to reach USD 10.7 billion by 2025, according to a new report by Grand View Research, Inc., at an 11.4% CAGR during the forecast period. DNA and gene chips have gained much success in providing high throughput capabilities for comprehensive genome studies to enhance disease knowledge and target them. This technology has emerged as a valuable and promising solution across various aspects of disease management. These factors have been driving the market.
Conventional means of gene analysis allow investigation of relatively small amounts of genes at a time, which further emphasizes on the uptake of DNA microarray technology. DNA microarray technology allows concurrent analysis of very large numbers of nucleic acid fragments in a single experiment.
Continuous development of new tools to support and enhance the reliability of DNA microarray technology is likely to drive this market at a significant pace in the foreseeable future. Furthermore, healthcare entities are engaged in exploiting novel solutions for enhancing and combining data generated from gene chip with data generated from high throughput technologies. Mutually beneficial partnerships between microarray developers and pharmaceutical/biopharmaceutical companies for the acceleration of genomic and biomedical research activities is anticipated to spur market growth in the coming years.
Request a free sample copy or view report summary: DNA & Gene Chip Market Report
Based on product, consumables dominated the market with the largest share. This is due to the presence of a large number of entities engaged in providing reagents and kits associated with the use of DNA chips
The cancer treatment and diagnosis segment accounts for a significant share in the market owing to the rising inclination toward development of companion diagnostics and growing usage of DNA microarrays in cancer diagnosis and treatment
Implementation of gene chip for drug discovery is also expected to increase in the coming years owing to the growing demand for personalized medicine
By end use, academic/government research institutes accounted for the largest share in 2017. Ongoing research projects on gene expression analysis in these institutes have attributed to the estimated share
In terms of region, North America dominated the market in terms of revenue. High penetration of major revenue-generating companies in the U.S. has contributed to its leading share
Asia Pacific is projected to witness the fastest year-on-year growth owing to rising healthcare spending in developing economies and an increase in R&D investment
Some of the prominent market participants are Agilent Technologies; Thermo Fisher Scientific, Incorporated (Affymetrix, Inc.); Illumina, Inc.; Macrogen Inc.; and Arrayit Corporation. These players are engaged in mutual partnerships with research communities and other diagnostic firms for the use of gene chips for targeting disease prognosis.
Grand View Research has segmented the global DNA & gene chip market on the basis of application, product, end use, and region:
DNA & Gene Chip Application Outlook (Revenue, USD Million, 2014 - 2025)
Cancer diagnosis and treatment
Gene expression
Genotyping
Genomics
Drug discovery
Agricultural biotechnology
Others
DNA & Gene Chip Product Outlook (Revenue, USD Million, 2014 - 2025)
Consumables
Instrumentation
DNA & Gene Chip End-use Outlook (Revenue, USD Million, 2014 - 2025)
Academic & Government Research Institutes
Hospitals & Diagnostics Centers
Biotechnology & Pharmaceutical Companies
Others
DNA & Gene Chip Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Middle East & Africa
South Africa
"The quality of research they have done for us has been excellent..."